Medical technology company Vivos Therapeutics has entered a distribution agreement with United Kingdom-based GM Instruments to offer its NR6 Rhinomanometer.
Vivos Therapeutics specializes in diagnostic and treatment methods for patients suffering from dentofacial abnormalities, sleep apnea and snoring.
GM Instruments' NR6 Rhinomanometer is the only FDA-approved four-phase rhinomanometer used to calculate nasal airway resistance.
The deal provides Vivos with a new revenue stream and a competitive advantage as the sole distributor of the product, chair and CEO Kirk Huntsman said in a June 29 news release.